Reshma Rangwala

20.3k citations
42 papers · 9.5k · 2 hit papers · h-index 18

Impact in

  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • CAR-T cell therapy research
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Cancer Immunotherapy and Biomarkers 19
    • Pancreatic and Hepatic Oncology Research 6
    • HER2/EGFR in Cancer Research 5
    • Lung Cancer Treatments and Mutations 11
    • Renal cell carcinoma treatment 3

Reshma Rangwala

41 papers receiving 9.4k citations

Reshma Rangwala's Hit Papers

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial 2017 · 399 citations
3990+3+6Years since publication2.0k4.0k6.0k

Peers

Reshma Rangwala
Comparison fields: 5 of 112
  • Oncology 5.8k
  • Pulmonary and Respiratory Medicine 2.8k
  • Immunology 1.5k
  • Cancer Research 805
  • Physiology 119
Replace Todd M. Bauer with:
Todd M. Bauer United States
Mark N. Stein United States
Michael J. Pishvaian United States
Shumei Kato United States
Melissa L. Johnson United States
Ronnie Shapira‐Frommer Israel
Marisa Dolled‐Filhart United States
John D. Powderly United States
Manish R. Patel United States
Helen K. Angell United Kingdom
Reshma Rangwala relative to Todd M. Bauer United States Todd M. Bauer's profile →
Citations per field
00.5×1.5×1.8×
Todd M. Bauer · 1×
Citations per year

Countries citing papers authored by Reshma Rangwala

Since Specialization
Citations

This map shows the geographic impact of Reshma Rangwala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reshma Rangwala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reshma Rangwala more than expected).

Fields of papers citing papers by Reshma Rangwala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reshma Rangwala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reshma Rangwala. The network helps show where Reshma Rangwala may publish in the future.

Co-authors

The 25 scholars most cited alongside Reshma Rangwala, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Reshma Rangwala Line = papers co-authored together Reshma Rangwala links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Hit paper breakdown →
20167183
2
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Hit paper breakdown →
2017399
3 2014317
4 2014300
5 2017257
6 2017191
7 2019188
8 2005136
9 200267
10 200557
11 200256
12 201650
13 201743
14 201738
15 200235
16 202126
17 202018
18 201518
19 201517
20 201515

About Reshma Rangwala

Reshma Rangwala is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 42 papers that have together received 9.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Treatments and Mutations (11 papers), Phagocytosis and Immune Regulation (7 papers), Pancreatic and Hepatic Oncology Research (6 papers), Cancer Genomics and Diagnostics (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), HER2/EGFR in Cancer Research (5 papers) and Renal cell carcinoma treatment (3 papers). The work is most often cited by research in Oncology (5.8k citations), Pulmonary and Respiratory Medicine (2.8k citations), Immunology (1.5k citations), Cancer Research (805 citations) and Physiology (119 citations). Reshma Rangwala has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Rina Hui, Gregory M. Lubiniecki, Delvys Rodríguez‐Abreu, Maya Gottfried, Mary O’Brien, Julie R. Brahmer, Andrew Robinson, Nir Peled, Katsuyuki Hotta and Ali Tafreshi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Gynecologic Oncology and Autophagy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact